IMR Press / FBL / Volume 22 / Issue 1 / DOI: 10.2741/4470

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Binding kinetics in drug discovery – A current perspective

Show Less
1 Bayer Pharma AG, Lead Discovery Berlin, Muellerstrasse 178, 13353 Berlin, Germany
Academic Editor:Chung F. Wong
Front. Biosci. (Landmark Ed) 2017, 22(1), 21–47; https://doi.org/10.2741/4470
Published: 1 January 2017
(This article belongs to the Special Issue Drug-binding kinetics in drug discovery)
Abstract

The impact of target binding kinetics (BK) on the clinical performance of therapeutic agents is presently a topic of intense debate in drug discovery. While retrospective studies suggest that BK is a differentiating parameter in marketed medicines, it is yet unclear how this information could be used to prioritize drug candidates during lead optimization. Motivated by the question whether BK can be understood and rationally optimized, we review the most relevant literature in the field, with special focus on selected examples from our organization. First we discuss structure-kinetic relationships (SKR), and how they can be influenced by factors such as conformational changes, molecular flexibility, hydrogen bonds, hydrophobicity, water molecules and (reversible-) covalent bonds. We then introduce the methodologies currently used for the investigation of BK parameters, briefly commenting on their strengths, weaknesses and future trends. Finally, we present our current perspective on the integration of BK in the drug discovery process, aiming to stimulate further thoughts on this important subject.

Keywords
Binding Kinetics
Residence Time
Structure-Kinetic Relationships
On-Rate
Off-Rate
Review
Share
Back to top